展望未来，奈飞预计Q1每股收益为76美分，低于华尔街预期的82美分;Q1销售额预计为122亿美元，与 预期相符。奈飞暗示未来一年营收增长可能放缓，预计2026 年全年销售额将增长12%至14%，低于此前 设定的约15%的目标，达到507 亿美元至 517 亿美元，分析师预期为509.8亿美元。此外，周二，该公司 宣布了一项修订后的协议，已将对华纳兄弟和 HBO 的收购要约修改为全现金收购，将以每股27.75美元 的现金收购这些部门，此前该公司曾提出以现金加股票的方式收购。 智通财经APP获悉，周三，奈飞(NFLX.US)盘前跌超7%，报80.89美元。消息面上，奈飞公布了第四季 度业绩，基本超出华尔街预期;但对未来几个月的业绩预测较为谨慎，理由是节目支出增加以及与华纳 兄弟探索频道(WBD.US)完成交易的成本。Q4销售额为121亿美元(同比增长18%)，每股收益为56美分， 均超出分析师预期。2025年全年销售额达到452亿美元，比上年增长16%。 Seeking Alpha分析师Julian Lin 表示："我怀疑该股财报发布后的疲软是多种因素共同作用的结果，包括 财报发布前该股估值过高、管理层对利润率扩 ...

Core Viewpoint - The recent earnings season for U.S. stocks has shown that actual profits significantly exceeded market expectations, yet investors reacted with the worst stock price performance following earnings beats on record, indicating a cautious sentiment towards future guidance and macroeconomic uncertainties [1][5][15]. Group 1: Earnings Performance - Approximately 81% of S&P 500 companies reported actual profits that surpassed fourth-quarter consensus estimates, but their stock prices lagged the benchmark index by an average of 1.1 percentage points, marking the worst relative performance since 2017 [1][15]. - Companies like 3M and State Street saw significant stock price declines despite beating earnings expectations, as investors focused on their bleak forecasts [2][15]. - Netflix's disappointing earnings outlook led to a pre-market drop of about 6%, failing to provide a positive start to the earnings season for tech giants [2][15]. Group 2: Market Sentiment and Valuation - Investors are increasingly focused on management comments and earnings guidance, particularly regarding AI computing demand and consumer health, which are critical narratives for the ongoing bull market [6][13]. - The current market threshold for upward movement is not merely beating consensus expectations but rather providing strong forward guidance to justify high valuations in a sensitive macroeconomic environment [7][13]. - The S&P 500 is trading at approximately 22 times forward earnings, above the 10-year average of 19 times, indicating that any signs of weak demand could trigger significant sell-offs [13][15]. Group 3: Geopolitical and Economic Concerns - Concerns over geopolitical tensions and macroeconomic uncertainties, exacerbated by aggressive tariff threats from former President Trump, have led to increased scrutiny from investors in the historically high U.S. stock market [8][15]. - The potential for a global trade war has heightened investor caution, impacting sentiment towards the stock market as it enters its third year of a bull run [8][15]. Group 4: Specific Company Insights - TSMC reported exceptionally strong earnings, with a gross margin exceeding 60% and a projected revenue growth rate of nearly 30% for 2026, significantly boosting investor confidence in semiconductor stocks [14][15]. - The demand for DRAM and NAND storage chips remains robust, driven by the increasing importance of these products in AI training and inference systems, highlighting a critical growth area in the tech sector [13][14].

Group 1: Earnings Reports and Expectations - The earnings season for banks will commence with JPMorgan Chase and Bank of New York Mellon reporting on Tuesday, followed by Citigroup, Wells Fargo, and Bank of America on Wednesday, and Goldman Sachs and Morgan Stanley on Thursday [1] - Consensus expectations for Q4 earnings per share (EPS) show Citigroup leading with a 21% year-over-year growth among global systemically important banks, while Bank of New York Mellon is expected to grow by 15% in the trust bank category [1] - The most significant upward revisions in EPS consensus over the past six months are for Morgan Stanley (16% growth), Bank of New York Mellon (7.1% growth), and U.S. Bancorp [1] Group 2: Investment Banking and Market Activity - Investment banking revenue is projected to support Q4 performance, with Dealogic forecasting a 15% year-over-year increase in global investment banking revenue to $103 billion and a 42% rise in M&A deal volume to $5.1 trillion [1] - Morgan Stanley's model predicts a 9% year-over-year increase in investment banking fees for Q4, slightly below the market expectation of 11%, while M&A advisory fees are expected to rise by 15% [2] - The trading revenue is anticipated to grow by 8% year-over-year, with equity trading expected to increase by 12%, surpassing the 5% growth forecast for fixed income, foreign exchange, and commodities trading [2] Group 3: Future Outlook and Strategic Insights - Analysts expect that transaction, wealth management, and investment banking will drive growth in 2026, with a slowdown in net interest income growth due to declining interest rates [3] - The banks with the best prospects for net interest income growth in the coming year are Bank of America, JPMorgan Chase, and Bank of New York Mellon, while Morgan Stanley and JPMorgan are preferred in trading business [3] - In the M&A sector, Morgan Stanley, Goldman Sachs, and JPMorgan are viewed positively for their performance [3] Group 4: Accounting Changes and Financial Impact - Bank of America announced a change in accounting treatment related to tax-advantaged housing and renewable energy investments, which will minimally impact annualized net income [2] - Following the accounting change, Bank of America's retained earnings as of September 30, 2025, will decrease by $1.7 billion, reflecting cumulative effects from the timing differences in expense recognition [2]

Investment Rating - The investment rating for the industry is "Positive" and maintained [8] Core Insights - In FY2025Q3, the company achieved revenue of $2.57 billion, a year-on-year increase of 7%, exceeding market expectations (Bloomberg consensus forecast of $2.48 billion) [2][6] - Gross margin decreased by 2.9 percentage points to 55.6%, primarily impacted by rising tariffs, increased discounts, and foreign exchange losses [2][6] - Operating profit margin fell by 3.5 percentage points to 17.0%, while net profit decreased by 13% to $310 million, with a net profit margin of 12.0%, down 2.7 percentage points year-on-year [2][6] Revenue Breakdown - By region, FY2025Q3 revenue for the U.S./North America/Greater China was $1.38 billion/-2% /$1.73 billion/-3% /$510 million/+42%, with Greater China benefiting from e-commerce growth and offline store expansion, while North America faced pressure due to weak store traffic, declining average transaction value, and lower conversion rates [7] - By channel, FY2025Q3 revenue from direct sales/e-commerce was $1.21 billion/+$0.107 billion/+13%, with direct sales growth slowing sequentially, while e-commerce maintained strong growth [7] - By category, FY2025Q3 revenue for women's/men's/other products was $1.64 billion/+6% /$600 million/+8% /$320 million/+12%, showing steady performance across categories [7] Inventory and Guidance - As of FY2025Q3, the company's inventory increased by 11% year-on-year to $2 billion, with expectations for unit inventory growth in FY2026Q4 and dollar inventory growth in double digits year-on-year [12] - The company slightly raised its full-year guidance, expecting FY2025 revenue of $10.962 to $11.047 billion, a year-on-year increase of 4% (previous guidance was $10.85 to $11 billion, a 2% to 4% increase) [12]

Core Viewpoint - Pfizer has released a conservative earnings guidance for 2026, planning to invest in pipeline assets to counteract declining sales from COVID-related products and shrinking revenue from older drugs [3][5][10]. Financial Projections - The company expects adjusted earnings per share for 2026 to be in the range of $2.80 to $3.00, slightly below analysts' expectations of $3.05 [11]. - Pfizer anticipates revenue for 2026 to reach between $59.5 billion and $62.5 billion, consistent with the 2025 revenue guidance of $62 billion [4][11]. Sales Decline Factors - The revenue outlook is impacted by a projected decline of approximately $1.5 billion in sales from COVID vaccines and the oral antiviral drug Paxlovid, bringing their total sales down to $5 billion [4][11]. - Additionally, the loss of market exclusivity for several products is expected to contribute to another $1.5 billion decline in sales [4][11]. Patent Expiration and Market Competition - Pfizer's CFO indicated that the peak of patent expirations is expected between 2026 and 2028, potentially affecting revenues by $17 billion due to the expiration of patents and regulatory exclusivities [6][11]. - Key products, including the anticoagulant drug Eliquis, will face pricing pressures due to new government regulations [12]. Cost Management and Restructuring - The company has exceeded its cost-saving targets for 2025 and aims to achieve over $7 billion in cost reductions by 2027, with most savings expected to materialize in the coming year [13]. - Analysts noted that the earnings outlook aligns with market expectations, and the cost restructuring plan may help mitigate pressures from declining COVID-related business [12][13]. Regulatory Environment and Pricing Agreements - Pfizer has entered a significant drug pricing agreement with the Trump administration, committing to provide existing drugs at the lowest prices available in other developed countries [14]. - The company plans to increase discounts for its Medicare business, which has been factored into the 2026 earnings guidance, considering the impact of price compression and margin contraction [14].

Core Insights - Lululemon's CEO Kevin McDonald is stepping down, with the current CFO and chief commercial officer taking over as co-CEOs during the search for a permanent successor [1][2] - The company's earnings for the third quarter were reported at $2.59 billion, exceeding analyst expectations of $2.25 billion, marking a 7% increase year-over-year [2][3] - Gross margin improved to 55.6%, surpassing the expected 54.3%, despite concerns about discounting during the Black Friday weekend [4] Financial Performance - Third quarter revenues reached $2.59 billion, higher than the anticipated $2.48 billion [2][3] - Same-store sales increased by 1%, but comparable sales in America decreased by 5%, indicating that international sales were a key driver of growth [3] - A billion-dollar increase in the company's buyback program was announced [4] Future Guidance - The guidance for the fourth quarter is weaker than expected, with earnings projected between $4.66 and $4.76, compared to the previous expectation of $5.03 [5] - Fourth quarter revenue expectations are set between $3.5 billion and $3.59 billion, slightly below the anticipated $3.6 billion [5]

据悉，英美烟草首席执行官Tadeu Marroco同时提及公司明年面临的其他压力，其中包括澳大利亚烟草 监管政策趋严带来的冲击，以及对新兴产品品类的持续投入，也将对利润增长形成一定压制。根据英美 烟草的最新指引，2026年营收增速将落在3%-5%的中期目标区间下限，经调整后的营业利润增速预计为 4%-6%。 消息面上，思摩尔国际大客户英美烟草(BTI.US)近日公布最新业绩指引，预计其2026年业绩将处于中期 目标的低端，原因是美国电子烟市场的监管压力和激烈竞争，抵消了其业务组合中其他领域的强劲增 长。 思摩尔国际(06969)早盘跌超8%，较年内高点23.92港元已腰斩，截至发稿，跌7.65%，报11.34港元，成 交额3.13亿港元。 ...

Core Insights - Donaldson Company, Inc. reported strong first-quarter fiscal 2026 results, with sales increasing by 3.9% year over year to $935.4 million, surpassing the consensus estimate of $922.9 million [1] - GAAP net earnings rose to $113.9 million (97 cents per share) from $99.0 million (81 cents per share) in the previous year, while adjusted EPS was 94 cents, exceeding the consensus of 92 cents [1] Financial Guidance - The company raised its fiscal 2026 guidance for adjusted EPS to a range of $3.95-$4.11, compared to the previous range of $3.92-$4.08, and above the consensus of $4.01 [2] - Sales growth guidance was revised to 1%-5% year over year, up from the earlier guidance of 1%-3%, with an expected pricing benefit of around one percentage point [2] Market Performance - CEO Tod Carpenter highlighted that the company gained market share in key businesses and increased replacement part sales, achieving a 13% growth in adjusted EPS from a 4% sales growth [3] - Following the earnings announcement, Donaldson shares dipped by 1.8%, trading at $92.16 [3] Analyst Ratings - Baird analyst Richard Eastman maintained an Outperform rating on Donaldson and raised the price target from $96 to $100 [6] - Stifel analyst Adam Farley maintained a Hold rating and increased the price target from $90 to $96 [6]

Core Viewpoint - Chow Tai Fook's stock has declined over 3%, currently trading at HKD 13.82, with a trading volume of HKD 218 million [1] Financial Performance - For the six months ending September 30, 2025, Chow Tai Fook reported a revenue of HKD 38.986 billion, a year-on-year decrease of 1.07% [1] - The company's profit attributable to shareholders was HKD 2.534 billion, reflecting a year-on-year increase of 0.16% [1] - The gross profit margin narrowed by 0.9 percentage points to 30.5% compared to the previous year [1] Market Expectations - According to Daiwa's report, Chow Tai Fook's revenue and net profit for the first half of the 2026 fiscal year were 2% to 3% lower than market expectations [1] - Despite the lower-than-expected performance, Daiwa believes that the positive factors in the results outweigh the negatives [1] - The company has increased its dividend payout ratio and per-share dividend, while also raising its earnings guidance for the second half of the 2026 fiscal year, which Daiwa considers conservative [1]

Core Viewpoint - Daiwa has raised its earnings per share forecast for Chow Tai Fook (01929) for the years 2026 to 2028 by 2% to 5%, and increased the 12-month target price from HKD 15.5 to HKD 18, maintaining a price-to-earnings ratio of 18 times and reiterating a "Buy" rating [1] Financial Performance - Chow Tai Fook's revenue and net profit for the first half of the fiscal year ending September 2026 were 2% to 3% lower than market expectations, but the company believes that positive factors outweigh negative ones [1] - The company has increased its dividend payout ratio and per-share dividend, while also raising its guidance for the second half of the fiscal year 2026, which Daiwa considers conservative [1] Gold Price Impact - During the first half of fiscal year 2026, the price of gold increased by 40% year-on-year, leading to a hedge loss of approximately HKD 3.1 billion [1] - If gold prices remain at the current level (approximately USD 4,100 per ounce) before the end of fiscal year 2026, an estimated additional hedge loss of about HKD 2 billion is expected in the second half of the fiscal year [1] - However, higher gross margins are anticipated to offset these impacts, with management raising its gross margin guidance to 31% to 32% following a significant retail price increase, including a 20% price hike on gold products [1] Sales Growth Outlook - Management has maintained its previous guidance for revenue and same-store sales growth in the low single digits and mid-single digits, but Daiwa believes this is overly conservative, expecting a low double-digit growth in same-store sales for the first three quarters [1]